1. Scrip
  2. >>Drug Pricing

Future Value Creation Depends On Incorporating Data-Driven Technology, EY Concludes

 
• By Joseph Haas

Biopharmas and other life sciences firms risk getting left behind by technology firms if they don't begin addressing patient needs more directly through data-driven technological advances, such as those to aid clinical development or treatment decisions with real-time patient data.

Medical app

Traditional life sciences companies, including the biopharmaceutical industry, run the risk of being passed by due to the increasing activity by technology companies in health care, warns EY Global Life Sciences Industry Leader Pamela Spence. She thinks partnering might be the best solution.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Mounjaro In India: Price Differential, Window Of Opportunity

 
• By Anju Ghangurde

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

Stelara Biosimilars Storm US Market With 85% Discounts Ahead Of Price Drop In Medicare

 
• By Cathy Kelly

The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.

Alnylam Joins Competitive ATTR-CM Market With Amvuttra Approval

 
• By Jessica Merrill

Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.

More from Scrip

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Trump’s Tariff Rollercoaster Keeps Pharma On Edge

 
• By Jessica Merrill

The rollout of Trump’s tariff plan has been a policy whiplash, but despite a 90-day pause on tariffs, it appears the US president is still holding a grudge with industry over drug pricing.

Trump’s Tariffs Add To European Warning Of $100bn US Exodus

 
• By Andrew McConaghie

European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.